AMRX: Amneal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on AMRX: Amneal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,370.23
Enterprise Value ($M) 4,859.42
Book Value ($M) -59.39
Book Value / Share -0.42
Price / Book -39.91
NCAV ($M) -1,914.19
NCAV / Share -6.15
Price / NCAV -1.24

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.84
Current Ratio 1.40

Balance Sheet (mrq) ($M)
Current Assets 1,510.45
Assets 3,365.25
Liabilities 3,424.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,793.96
Operating Income 350.84
Net Income -116.89
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 295.10
Cash from Investing -63.00
Cash from Financing -211.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-14 13G/A Mahesh Akram 6.56 -23.45
04-30 13G Vanguard Group Inc 5.02 15.54
03-17 13D/A Patel Tushar Bhikhubhai 15.70 -9.33
02-10 13G/A UBS Group AG
01-23 13D/A Patel Dipan 7.70 -11.43
10-31 13D/A Patel Chirag K. 7.10 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-06 359,658 2,641,749 13.61
2025-06-05 372,727 1,252,618 29.76
2025-06-04 350,146 1,505,134 23.26
2025-06-03 99,318 892,423 11.13
2025-06-02 201,203 1,364,464 14.75

(click for more detail)

Similar Companies
AMGN – Amgen Inc. AMLX – Amylyx Pharmaceuticals, Inc.
AMPH – Amphastar Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc.


Financial data and stock pages provided by
Fintel.io